A daily compilation of articles, manuscripts, and news focused on the ADC market and compiled for the scientists who are making the cure everyday.
Wednesday, May 15, 2019
Iconic Therapeutics is using Zymelink Tech for first ADC
Iconic is going after Tissue Factor targets in oncology, and their molecule ICON-2 is their first ADC product expected to head to the clinic.
Zymeworks is starting to make some waves. Is this a company to keep an eye on?
Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics
Subscribe to: Post Comments (Atom)
Post a Comment